CO5660297A2 - Anticuerpos contra el receptor de il-21 humano y usos de los mismos - Google Patents

Anticuerpos contra el receptor de il-21 humano y usos de los mismos

Info

Publication number
CO5660297A2
CO5660297A2 CO05093185A CO05093185A CO5660297A2 CO 5660297 A2 CO5660297 A2 CO 5660297A2 CO 05093185 A CO05093185 A CO 05093185A CO 05093185 A CO05093185 A CO 05093185A CO 5660297 A2 CO5660297 A2 CO 5660297A2
Authority
CO
Colombia
Prior art keywords
receiver
human
same
antibodies against
amino acid
Prior art date
Application number
CO05093185A
Other languages
English (en)
Inventor
Deborah Ann Young
Matthew J Whitters
Viia Valge Archer
Mary Collins
Andrew James Williams
Joanne Witek
Original Assignee
Wyeth Corp
Cambridge Antibody Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33029874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5660297(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp, Cambridge Antibody Tech filed Critical Wyeth Corp
Publication of CO5660297A2 publication Critical patent/CO5660297A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Abstract

1.- Un anticuerpo aislado CARACTERIZADO PORQUE comprende una secuencia de aminoácidos el cual es al menos un 95% idéntica a una secuencia de aminoácidos seleccionada entre las SEQ ID N° 1, 2, 3, 19, 20, 21, 47, 48, 49, 65, 66, 67, 83, 84, 85, 101, 102, 103, 119, 120, 121, 137, 138, y 139, donde dicho anticuerpo se une selectivamente a un receptor de IL-21.
CO05093185A 2003-03-14 2005-09-14 Anticuerpos contra el receptor de il-21 humano y usos de los mismos CO5660297A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45433603P 2003-03-14 2003-03-14

Publications (1)

Publication Number Publication Date
CO5660297A2 true CO5660297A2 (es) 2006-07-31

Family

ID=33029874

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05093185A CO5660297A2 (es) 2003-03-14 2005-09-14 Anticuerpos contra el receptor de il-21 humano y usos de los mismos

Country Status (20)

Country Link
US (2) US7495085B2 (es)
EP (2) EP1603949B9 (es)
JP (1) JP4914209B2 (es)
KR (1) KR20050119120A (es)
CN (2) CN1777621A (es)
AR (1) AR043616A1 (es)
AT (1) ATE456581T1 (es)
AU (1) AU2004221876B2 (es)
BR (1) BRPI0408315A (es)
CA (1) CA2518371A1 (es)
CL (1) CL2004000534A1 (es)
CO (1) CO5660297A2 (es)
DE (1) DE602004025332D1 (es)
ES (1) ES2340280T3 (es)
MX (1) MXPA05009556A (es)
NO (1) NO20054170L (es)
NZ (1) NZ542306A (es)
RU (1) RU2005131852A (es)
WO (1) WO2004083249A2 (es)
ZA (1) ZA200507067B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
WO2004007682A2 (en) * 2002-07-15 2004-01-22 Wyeth Methods and compositions for modulating t helper (th) cell development and function
RU2005131852A (ru) 2003-03-14 2006-04-20 Уайт (Us) Антитела против человеческого рецептора il-21 и их применение
CN1849131A (zh) * 2003-03-21 2006-10-18 Wyeth公司 用白介素－21/白介素－21受体的激动剂治疗免疫性疾病
EP1983000B1 (en) 2003-11-21 2015-09-02 UCB Biopharma SPRL Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
US20060024268A1 (en) * 2004-05-19 2006-02-02 Wyeth Modulation of immunoglobulin production and atopic disorders
EP1773394A2 (en) * 2004-08-05 2007-04-18 Wyeth a Corporation of the State of Delaware Antagonizing interleukin-21 receptor activity
EP2322622A3 (en) * 2005-03-25 2012-03-07 National Research Council of Canada Method for isolation of soluble polypeptides
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
EP2567973B1 (en) 2005-11-28 2014-05-14 Zymogenetics, Inc. IL-21 antagonists
JP2009517406A (ja) * 2005-11-28 2009-04-30 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１受容体アンタゴニスト
PL2540820T3 (pl) 2005-12-09 2018-05-30 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Środki i sposoby wpływania na stabilność komórek wytwarzających przeciwciała
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
US20070253950A1 (en) * 2006-03-21 2007-11-01 Wyeth Methods for Preventing and Treating Amyloidogenic Diseases
WO2008092084A2 (en) * 2007-01-26 2008-07-31 Centocor, Inc. Injectable non-aqueous suspension with high concentration of therapeutic agent
EP3351557A1 (en) 2007-06-29 2018-07-25 F. Hoffmann-La Roche AG Heavy chain mutant leading to improved immunoglobulin production
WO2009023267A2 (en) * 2007-08-15 2009-02-19 President And Fellows Of Harvard College Methods for modulating development and expansion of il-17 expressing cells
AU2008364115B2 (en) * 2007-12-07 2013-11-21 Zymogenetics, Inc. Anti-human IL-21 monoclonal antibodies
WO2009111889A1 (en) * 2008-03-13 2009-09-17 The Hospital For Sick Children Lymphocyte control of obesity and insulin resistance
CN102149403A (zh) * 2008-05-23 2011-08-10 惠氏有限责任公司 利用白介素-21受体结合蛋白的治疗方法
PE20100141A1 (es) * 2008-05-23 2010-02-22 Wyeth Corp Proteina de union al receptor de interleuquina 21
JP2012504939A (ja) 2008-09-23 2012-03-01 ワイス・エルエルシー 架橋結合タンパク質による活性化シグナルの産生を予測するための方法
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
DK2454283T3 (en) 2009-07-15 2018-05-07 Aimm Therapeutics Bv METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
EP2596023A4 (en) * 2010-07-20 2014-03-05 Beth Israel Hospital COMPOSITIONS AND METHODS COMPRISING ANTAGONISTS OF IL-6 AND IL-21
JP6013356B2 (ja) 2010-12-02 2016-10-25 アイム・セラピューティクス・べー・フェー 高親和性抗体を製造するための手段および方法
EA027410B1 (ru) * 2011-04-29 2017-07-31 Селекта Байосайенсиз, Инк. Наноносители, вызывающие иммунную толерантность, для снижения ответной реакции цитотоксических t-лимфоцитов
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
WO2014153195A1 (en) 2013-03-14 2014-09-25 Bayer Healthcare Llc Monoclonal antibodies against antithrombin beta complexed with heparin
WO2015115892A1 (en) 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
AR099625A1 (es) * 2014-03-21 2016-08-03 Lilly Co Eli Anticuerpos de il-21
RU2708336C2 (ru) 2014-04-08 2019-12-05 Бостон Фармасьютикалс Инк. Связывающие молекулы, специфичные к ил-21, и области их применения
EP3368656A4 (en) * 2015-10-30 2019-07-17 The United States of America, as represented by the secretary, Department of Health and Human Services TARGETED CANCER THERAPY
EP3436060A4 (en) * 2016-03-31 2019-12-04 Eli Lilly and Company ANTIBODIES AGAINST IL-21 AND USES THEREOF
ES2949342T3 (es) * 2016-06-17 2023-09-27 Medigene Immunotherapies Gmbh Receptores de células T y usos de los mismos
WO2018045273A2 (en) * 2016-09-02 2018-03-08 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
CN109503715B (zh) * 2017-09-15 2023-12-15 科济生物医药（上海）有限公司 Il-4r的融合蛋白及其应用
JP2022539351A (ja) * 2019-06-26 2022-09-08 ザ・ジョンズ・ホプキンス・ユニバーシティ 制御性ｔ細胞をターゲットとして増殖させるための方法及び材料
CN114901687A (zh) * 2019-12-24 2022-08-12 迪哲(江苏)医药股份有限公司 新颖抗fgfr2b抗体
WO2023023150A2 (en) * 2021-08-18 2023-02-23 Hifibio (Hk) Limited Methods and compositions related to neutralizing antibodies against human coronavirus
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
CA2196200A1 (en) 1994-07-29 1996-02-15 Michael Joseph Browne Novel compounds
FR2724182B1 (fr) * 1994-09-02 1996-12-13 Pasteur Institut Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations
SI9720020B (en) 1996-02-09 2001-12-31 Basf Ag Human antibodies that bind human TNF alpha
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
EP0812913A3 (en) 1996-06-12 1999-08-04 Smithkline Beecham Corporation HR-1 receptor, a receptor of the cytokine receptors family
WO1997047741A1 (en) 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
WO1997047742A1 (en) 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
AUPO224696A0 (en) 1996-09-11 1996-10-03 Amrad Operations Pty. Limited A novel haemopoietin receptor and genetic sequences encoding same
JP2001508309A (ja) 1997-01-16 2001-06-26 ジェネティックス・インスチチュート・インコーポレーテッド ヘマトポイエチン受容体スーパーファミリーのメンバー
US6350892B1 (en) 1997-09-23 2002-02-26 Bristol-Myers Squibb Company Trifluoromethyl ketone analogs as selective cPLA2 inhibitors
US20010025022A1 (en) 1997-11-26 2001-09-27 Kikly Kristine Kay Hnovilr
US7189400B2 (en) 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
AU759689B2 (en) 1998-06-24 2003-04-17 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor proteins
AU5104799A (en) 1998-08-04 2000-02-28 Regeneron Pharmaceuticals, Inc. Novel orphan cytokine receptors
US6576744B1 (en) 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
US6803451B2 (en) 1998-09-23 2004-10-12 Zymogenetics, Inc. Cytokine receptor zalpha11 polypeptides
DK1115862T3 (da) 1998-09-23 2009-11-16 Zymogenetics Inc Cytokinreceptor Zalpha11
US6355788B1 (en) * 1998-10-15 2002-03-12 Zymogenetics, Inc. Follistatin-related protein zfsta2
EP1124851A1 (en) 1998-11-06 2001-08-22 Smithkline Beecham Corporation Hnovilr
ATE377076T1 (de) 1999-03-09 2007-11-15 Zymogenetics Inc Humanes cytokin als ligand des zalpha rezeptors und dessen verwendungen
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
IL145134A0 (en) 1999-03-25 2002-06-30 Knoll Gmbh Human antibodies that bind human il-12 and methods for producing
WO2000069880A1 (en) 1999-05-18 2000-11-23 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
US20020090680A1 (en) 1999-05-18 2002-07-11 Millennium Pharmaceuticals, Inc. Novel IL-9/IL-2 receptor-like molecules and uses thereof
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
AU7676300A (en) 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use
EP1230368A2 (en) 1999-11-18 2002-08-14 Schering Corporation Mammalian receptor proteins; related reagents and methods
BR0107862A (pt) 2000-01-27 2002-11-05 American Cyanamid Co Método para a preparação de derivados do ácido alfa-sulfonil hidroxâmico
DE60125543T2 (de) * 2000-04-05 2007-10-04 Zymogenetics, Inc., Seattle Löslicher zytokinrezeptor zalpha11
AU6308801A (en) 2000-05-11 2001-11-20 Genetics Inst Mu-1, member of the cytokine receptor family
NZ522700A (en) * 2000-06-16 2006-02-24 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
EP1432431B1 (en) * 2001-10-04 2017-05-10 Genetics Institute LLC Methods and compositions for modulating interleukin-21 activity
AU2002336676A1 (en) 2001-11-05 2003-05-19 Zymogenetics, Inc Il-21 antagonists
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
WO2004007682A2 (en) * 2002-07-15 2004-01-22 Wyeth Methods and compositions for modulating t helper (th) cell development and function
RU2005131852A (ru) 2003-03-14 2006-04-20 Уайт (Us) Антитела против человеческого рецептора il-21 и их применение
CN1849131A (zh) * 2003-03-21 2006-10-18 Wyeth公司 用白介素－21/白介素－21受体的激动剂治疗免疫性疾病
US20060024268A1 (en) * 2004-05-19 2006-02-02 Wyeth Modulation of immunoglobulin production and atopic disorders
EP1773394A2 (en) 2004-08-05 2007-04-18 Wyeth a Corporation of the State of Delaware Antagonizing interleukin-21 receptor activity
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2009100035A2 (en) 2008-02-01 2009-08-13 Wyeth Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)

Also Published As

Publication number Publication date
CL2004000534A1 (es) 2005-03-04
ZA200507067B (en) 2006-12-27
DE602004025332D1 (de) 2010-03-18
US8143385B2 (en) 2012-03-27
WO2004083249A2 (en) 2004-09-30
WO2004083249A3 (en) 2004-12-09
CN102040662A (zh) 2011-05-04
MXPA05009556A (es) 2005-11-16
KR20050119120A (ko) 2005-12-20
US20100297151A1 (en) 2010-11-25
EP2184298A1 (en) 2010-05-12
US20040265960A1 (en) 2004-12-30
NZ542306A (en) 2008-04-30
US7495085B2 (en) 2009-02-24
EP1603949B8 (en) 2010-03-10
EP1603949B1 (en) 2010-01-27
NO20054170D0 (no) 2005-09-07
BRPI0408315A (pt) 2006-03-07
JP2007525159A (ja) 2007-09-06
AU2004221876A1 (en) 2004-09-30
ATE456581T1 (de) 2010-02-15
CA2518371A1 (en) 2004-09-30
RU2005131852A (ru) 2006-04-20
EP1603949B9 (en) 2011-02-02
CN1777621A (zh) 2006-05-24
NO20054170L (no) 2005-12-05
ES2340280T3 (es) 2010-06-01
EP1603949A2 (en) 2005-12-14
AU2004221876B2 (en) 2011-05-26
JP4914209B2 (ja) 2012-04-11
AR043616A1 (es) 2005-08-03

Similar Documents

Publication Publication Date Title
CO5660297A2 (es) Anticuerpos contra el receptor de il-21 humano y usos de los mismos
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
CO6220978A2 (es) Anticuerpos dirigidos a proteina-1 quimio-tactica de monocitos (mcp-1)y sus usos
CY1121580T1 (el) ΝΕΟΙ ΠΡΟΑΓΩΓΕΙΣ β-ΑΚΤΙΝΗΣ ΚΑΙ RPS21 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
CR7875A (es) Variantes de inmunoglobina y usos de esto
RS54133B1 (en) ANTI-IL-6 ANTIBODIES, PREPARATIONS, PREPARATION AND USE PROCEDURES
ZA200501054B (en) Transplant acceptance inducing cells of monocytic origin and their preparation and use.
MX341370B (es) Antagonistas anti - beta7 humanizados y usos para los mismos.
EA200800812A1 (ru) Композиции антитела против cd3
ECSP066379A (es) Anticuerpos rg1 y usos de los mismos
RS54468B1 (en) MONOCLONAL ANTIBODIES AGAINST CLAUDINE-18 FOR THE CANCER TREATMENT
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
PE20130643A1 (es) Conjugados de anticuerpos multifuncionales
EA200301213A1 (ru) Лиганды рецепторов 5-ht и их применение
EA200800601A1 (ru) Связывающие fas антитела
CY1105980T1 (el) Βελτιωμενη διαδικασια παρασκευης υδροβρωμικου αλατος του αλφα-πολυμορφικου ελετριπτανιου
PE20050962A1 (es) Anticuerpos completamente humanos contra 4-1bb humano
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
CY1109904T1 (el) Προαγωγεας της il-18bp, η παρασκευη και χρηση του
AU2003259750A8 (en) Methods and compositions for targeting secretory lysosomes
EA200601030A1 (ru) 7α,17α-ЗАМЕЩЁННЫЕ 11β-ГАЛОГЕНОСТЕРОИДЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ НА ИХ ОСНОВЕ
TNSN06443A1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de recepteurs de chimiokines
TW200617021A (en) Isolated photoprotein aequorin y89f, and its use
WO2003048320A3 (en) Novel motor protein of p. falciparum and methods for its use

Legal Events

Date Code Title Description
FC Application refused